[go: up one dir, main page]

CN118184599A - Preparation method of amoenavir intermediate - Google Patents

Preparation method of amoenavir intermediate Download PDF

Info

Publication number
CN118184599A
CN118184599A CN202410226549.6A CN202410226549A CN118184599A CN 118184599 A CN118184599 A CN 118184599A CN 202410226549 A CN202410226549 A CN 202410226549A CN 118184599 A CN118184599 A CN 118184599A
Authority
CN
China
Prior art keywords
acid
reaction
nitrobenzene
oxadiazole
oxime
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410226549.6A
Other languages
Chinese (zh)
Inventor
郑波
杨炼
龙平良
奚兴凤
邹春兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
YaoPharma Co Ltd
Chongqing Carelife Pharmaceutical Co Ltd
Original Assignee
YaoPharma Co Ltd
Chongqing Carelife Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by YaoPharma Co Ltd, Chongqing Carelife Pharmaceutical Co Ltd filed Critical YaoPharma Co Ltd
Priority to CN202410226549.6A priority Critical patent/CN118184599A/en
Publication of CN118184599A publication Critical patent/CN118184599A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

本发明提供了一种质子酸催化的阿莫奈韦中间体3‑(4‑硝基苯)‑1,2,4‑噁二唑的合成方法,该方法包括向4‑硝基苄胺肟的原甲酸三乙酯溶液中加入质子酸的步骤。该方法反应条件温和,操作简单,所得产物纯度好,收率高。The invention provides a protonic acid-catalyzed synthesis method of an amonetvir intermediate 3-(4-nitrobenzene)-1,2,4-oxadiazole, the method comprising the step of adding a protonic acid to a triethyl orthoformate solution of 4-nitrobenzylamide oxime. The method has mild reaction conditions, simple operation, good product purity and high yield.

Description

一种阿莫奈韦中间体的制备方法A preparation method of an amoenavir intermediate

技术领域Technical Field

本发明属于药物化学领域,具体涉及一种阿莫奈韦中间体3-(4-硝基苯)-1,2,4-噁二唑的制备方法。The invention belongs to the field of pharmaceutical chemistry, and specifically relates to a method for preparing an amonetir intermediate 3-(4-nitrobenzene)-1,2,4-oxadiazole.

背景技术Background technique

阿莫奈韦(Amenamevir)是由日本安斯泰来制药(Astellas Pharma Inc)公司研发的一种小分子药物,具有抑制疱疹病毒DNA复制必须的酶的螺旋酶、引物酶复合体的活性、抑制双链DNA的开裂及RNA引物合成的作用,临床主要用于带状疱疹的治疗。该药于2017年07月通过日本PMDA批准上市,其结构式如下:Amenamevir is a small molecule drug developed by Astellas Pharma Inc. of Japan. It has the function of inhibiting the activity of the helicase and primase complexes, which are enzymes necessary for the DNA replication of herpes virus, and inhibiting the cleavage of double-stranded DNA and the synthesis of RNA primers. It is mainly used in the treatment of herpes zoster. The drug was approved for marketing by the Japanese PMDA in July 2017. Its structural formula is as follows:

.

3-(4-硝基苯)-1,2,4-噁二唑作为制备阿莫奈韦的关键中间体,其质量及工艺严重影响着阿莫奈韦的应用及推广。3-(4-nitrobenzene)-1,2,4-oxadiazole is a key intermediate in the preparation of amounevir. Its quality and process seriously affect the application and promotion of amounevir.

目前公开的3-(4-硝基苯)-1,2,4-噁二唑制备方法主要有以下两种。There are two main methods for preparing 3-(4-nitrobenzene)-1,2,4-oxadiazole disclosed so far.

专利WO2020038812A1/US2009239848A1公开了一种制备3-(4-硝基苯)-1,2,4-噁二唑的方法:向4-硝基苄胺肟的原甲酸三乙酯溶液中加入三氟化硼乙醚溶液,反应完成后除去溶剂,得到目标产物。该方法有以下几个缺陷。首先该方法收率低,仅55%;其次,所用的三氟化硼乙醚溶液价格贵且用量大;第三,该方法需通过蒸馏除去高沸点的原甲酸三乙酯,操作复杂。Patent WO2020038812A1/US2009239848A1 discloses a method for preparing 3-(4-nitrobenzene)-1,2,4-oxadiazole: adding a boron trifluoride ether solution to a triethyl orthoformate solution of 4-nitrobenzylamine oxime, removing the solvent after the reaction is completed, and obtaining the target product. This method has the following defects. First, the yield of this method is low, only 55%; second, the boron trifluoride ether solution used is expensive and the amount used is large; third, this method requires distillation to remove the high-boiling triethyl orthoformate, which is complicated to operate.

专利WO2012009678A1公开了另外一种制备3-(4-硝基苯)-1,2,4-噁二唑的方法:将4-硝基苄胺肟的原甲酸三乙酯溶液加热至回流,反应结束后减压除去溶剂,得到目标产物。该方法收率高(92%),但反应温度较高(约140~150℃),且需要通过蒸馏除去高沸点的原甲酸三乙酯。另外我们对该工艺进行重现时发现,在该条件下会生成大量杂质对硝基苯甲腈,该杂质会进一步衍生并带到阿莫奈韦成品且难以去除;此外,该反应进行不彻底,反应液中有大量的中间态存在。Patent WO2012009678A1 discloses another method for preparing 3-(4-nitrobenzene)-1,2,4-oxadiazole: a solution of triethyl orthoformate of 4-nitrobenzylamine oxime is heated to reflux, and after the reaction is completed, the solvent is removed under reduced pressure to obtain the target product. This method has a high yield (92%), but the reaction temperature is relatively high (about 140-150°C), and the high-boiling triethyl orthoformate needs to be removed by distillation. In addition, when we reproduced the process, we found that a large amount of impurity p-nitrobenzonitrile would be generated under this condition, which would be further derived and carried to the finished product of amonetavir and was difficult to remove; in addition, the reaction was not thorough, and a large amount of intermediates existed in the reaction solution.

专利JP2005336101A公开了在4-硝基苄胺肟和原甲酸三乙酯混合溶液中,加入异丙醇、甲醇或乙醇混合,再在20~30℃条件下滴加98%硫酸,在相应温度条件下反应后,降温析晶、过滤得到目标产物。该方法需使用浓硫酸,对生产设备的耐腐蚀要求高。Patent JP2005336101A discloses that isopropanol, methanol or ethanol are added to a mixed solution of 4-nitrobenzylamine oxime and triethyl orthoformate, and then 98% sulfuric acid is added dropwise at 20-30°C. After the reaction is carried out under the corresponding temperature conditions, the target product is obtained by cooling, crystallizing and filtering. This method requires the use of concentrated sulfuric acid, and has high corrosion resistance requirements for production equipment.

因此,开发一种温和、经济、操作简单的制备3-(4-硝基苯)-1,2,4-噁二唑的方法很有必要。Therefore, it is necessary to develop a mild, economical and easy-to-operate method for preparing 3-(4-nitrobenzene)-1,2,4-oxadiazole.

发明内容Summary of the invention

本发明提供一种阿莫奈韦中间体3-(4-硝基苯)-1,2,4-噁二唑的制备方法,其包括以下步骤:The present invention provides a method for preparing an amonetir intermediate 3-(4-nitrobenzene)-1,2,4-oxadiazole, which comprises the following steps:

(1)向4-硝基苄胺肟的原甲酸三乙酯溶液中,加入质子酸,升温反应;(1) Add protonic acid to a solution of 4-nitrobenzylamine oxime in triethyl orthoformate and heat to react;

(2)反应结束后,加入溶剂析晶,分离固体得到3-(4-硝基苯)-1,2,4-噁二唑。(2) After the reaction is completed, a solvent is added to crystallize, and the solid is separated to obtain 3-(4-nitrobenzene)-1,2,4-oxadiazole.

优选的,所述步骤(1)中,质子酸选自甲酸、乙酸、丙酸、丁酸、甲烷磺酸、对甲苯磺酸、柠檬酸和草酸中的一种或多种,优选甲酸。Preferably, in step (1), the protonic acid is selected from one or more of formic acid, acetic acid, propionic acid, butyric acid, methanesulfonic acid, p-toluenesulfonic acid, citric acid and oxalic acid, preferably formic acid.

优选的,所述步骤(1)中,质子酸与4-硝基苄胺肟的摩尔比为0.3~0.7。Preferably, in step (1), the molar ratio of protonic acid to 4-nitrobenzylamine oxime is 0.3-0.7.

优选的,所述步骤(1)中,升温反应时的温度为45~105oC。Preferably, in step (1), the temperature during the temperature-raising reaction is 45-105 ° C.

优选的,所述步骤(2)中,所述溶剂选自甲醇、乙醇、正丙醇、异丙醇、正丁醇、异丁醇和叔丁醇中的一种或多种,优选乙醇和叔丁醇。Preferably, in step (2), the solvent is selected from one or more of methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol and tert-butanol, preferably ethanol and tert-butanol.

本发明的方法采用廉价的质子酸作为催化剂,不需蒸馏高沸点原甲酸三乙酯,不使用强酸,反应条件温和,操作简单,所得产物纯度高、收率高,适合放大生产。The method of the invention adopts cheap protonic acid as a catalyst, does not need to distill high-boiling-point triethyl orthoformate, does not use strong acid, has mild reaction conditions, is simple to operate, has high purity and high yield of the obtained product, and is suitable for large-scale production.

具体实施方式Detailed ways

以下实施例是代表性,用于进一步理解和说明本发明的实质,但不以任何方式限制本发明的范围。The following examples are representative and are used to further understand and illustrate the essence of the present invention, but are not intended to limit the scope of the present invention in any way.

实施例1Example 1

向反应瓶中加入28.27g 4-硝基苄胺肟,100.64g原甲酸三乙酯,5.09g甲酸,加热至70±5℃反应3h,反应完成后滴加乙醇析晶,抽滤,滤饼减压干燥得3-(4-硝基苯)-1,2,4-噁二唑27.80g,收率93.19%,纯度100%。Add 28.27 g of 4-nitrobenzylamine oxime, 100.64 g of triethyl orthoformate, and 5.09 g of formic acid into the reaction bottle, heat to 70±5°C and react for 3 h. After the reaction is completed, add ethanol dropwise for crystallization, filter, and dry the filter cake under reduced pressure to obtain 27.80 g of 3-(4-nitrobenzene)-1,2,4-oxadiazole with a yield of 93.19% and a purity of 100%.

实施例2Example 2

向反应瓶中加入15.00 g 4-硝基苄胺肟,53.37g原甲酸三乙酯,1.16 g甲酸,加热至70±5℃反应6h,反应完成后滴加乙醇析晶,抽滤,滤饼减压干燥得3-(4-硝基苯)-1,2,4-噁二唑14.49g,收率91.55%,纯度99.8%。Add 15.00 g 4-nitrobenzylamine oxime, 53.37 g triethyl orthoformate, and 1.16 g formic acid into the reaction bottle, heat to 70±5°C and react for 6 h. After the reaction is completed, add ethanol dropwise for crystallization, filter, and dry the filter cake under reduced pressure to obtain 14.49 g of 3-(4-nitrobenzene)-1,2,4-oxadiazole with a yield of 91.55% and a purity of 99.8%.

实施例3Example 3

向反应瓶中加入1.04 kg 4-硝基苄胺肟,3.70kg原甲酸三乙酯,0.19kg甲酸,加热至100±5℃反应3h,反应完成后滴加乙醇析晶,抽滤,滤饼减压干燥得3-(4-硝基苯)-1,2,4-噁二唑0.99kg,收率90.21%,纯度99.1%。Add 1.04 kg 4-nitrobenzylamine oxime, 3.70 kg triethyl orthoformate, and 0.19 kg formic acid into the reaction bottle, heat to 100±5°C and react for 3 h. After the reaction is completed, add ethanol dropwise for crystallization, filter, and dry the filter cake under reduced pressure to obtain 0.99 kg of 3-(4-nitrobenzene)-1,2,4-oxadiazole, with a yield of 90.21% and a purity of 99.1%.

实施例4Example 4

向反应瓶中加入20.00 g 4-硝基苄胺肟,71.20g原甲酸三乙酯,3.60g甲酸,加热至50±5℃反应8h,反应完成后滴加乙醇析晶,抽滤,滤饼减压干燥得3-(4-硝基苯)-1,2,4-噁二唑19.41g,收率91.9%,纯度98.8%。Add 20.00 g 4-nitrobenzylamine oxime, 71.20 g triethyl orthoformate, and 3.60 g formic acid into the reaction bottle, heat to 50±5°C and react for 8 h. After the reaction is completed, add ethanol dropwise for crystallization, filter, and dry the filter cake under reduced pressure to obtain 19.41 g of 3-(4-nitrobenzene)-1,2,4-oxadiazole with a yield of 91.9% and a purity of 98.8%.

实施例5Example 5

向反应瓶中加入30.00 g 4-硝基苄胺肟,160.20g原甲酸三乙酯,5.40g甲酸,加热至70±5℃反应4h后,反应完成后滴加乙醇析晶,离心减压干燥得3-(4-硝基苯)-1,2,4-噁二唑28.59g,收率90.31%,纯度99.5%。Add 30.00 g 4-nitrobenzylamine oxime, 160.20 g triethyl orthoformate, and 5.40 g formic acid into the reaction bottle, heat to 70±5°C and react for 4 hours. After the reaction is completed, add ethanol dropwise for crystallization, centrifuge and dry under reduced pressure to obtain 28.59 g of 3-(4-nitrobenzene)-1,2,4-oxadiazole, with a yield of 90.31% and a purity of 99.5%.

实施例6Example 6

向反应瓶中加入18.00g 4-硝基苄胺肟,64.08g原甲酸三乙酯,4.17g乙酸,加热至70±5℃反应5h,反应完成后滴加乙醇析晶,抽滤,滤饼减压干燥得3-(4-硝基苯)-1,2,4-噁二唑15.60g,收率82.15%,纯度99.8%。Add 18.00 g of 4-nitrobenzylamine oxime, 64.08 g of triethyl orthoformate, and 4.17 g of acetic acid to the reaction bottle, heat to 70±5°C and react for 5 hours. After the reaction is completed, add ethanol dropwise for crystallization, filter, and dry the filter cake under reduced pressure to obtain 15.60 g of 3-(4-nitrobenzene)-1,2,4-oxadiazole, with a yield of 82.15% and a purity of 99.8%.

实施例7Example 7

向反应瓶中加入10.00g 4-硝基苄胺肟,64.08g原甲酸三乙酯,3.48g草酸,加热至70±5℃反应3h,反应完成后滴加乙醇析晶,抽滤,滤饼减压干燥得3-(4-硝基苯)-1,2,4-噁二唑8.30g,收率78.66%,纯度97.6%。Add 10.00 g of 4-nitrobenzylamine oxime, 64.08 g of triethyl orthoformate, and 3.48 g of oxalic acid to the reaction bottle, heat to 70±5°C and react for 3 h. After the reaction is completed, add ethanol dropwise for crystallization, filter, and dry the filter cake under reduced pressure to obtain 8.30 g of 3-(4-nitrobenzene)-1,2,4-oxadiazole with a yield of 78.66% and a purity of 97.6%.

实施例8Example 8

向反应瓶中加入13.00g 4-硝基苄胺肟,70.00g原甲酸三乙酯,9.56g对甲苯磺酸一水合物,加热至70±5℃反应2h,反应完成后滴加乙醇析晶,抽滤,滤饼用碳酸氢钠水溶液,纯化水打浆后,减压干燥得3-(4-硝基苯)-1,2,4-噁二唑10.08g,收率73.48%,纯度93.8%。Add 13.00 g of 4-nitrobenzylamine oxime, 70.00 g of triethyl orthoformate, and 9.56 g of p-toluenesulfonic acid monohydrate to the reaction bottle, heat to 70±5°C for 2 h, add ethanol dropwise for crystallization after the reaction is completed, filter, and slurry the filter cake with sodium bicarbonate aqueous solution and purified water, and dry under reduced pressure to obtain 10.08 g of 3-(4-nitrobenzene)-1,2,4-oxadiazole, with a yield of 73.48% and a purity of 93.8%.

实施例9Example 9

向反应瓶中加入5.00 g 4-硝基苄胺肟,18.00g原甲酸三乙酯,0.64g甲酸,加热至70±5℃反应6h,反应完成后滴加乙醇析晶,抽滤,滤饼减压干燥得3-(4-硝基苯)-1,2,4-噁二唑4.88g,收率92.49%,纯度99.7%。Add 5.00 g 4-nitrobenzylamine oxime, 18.00 g triethyl orthoformate, and 0.64 g formic acid into the reaction bottle, heat to 70±5°C and react for 6 h. After the reaction is completed, add ethanol dropwise for crystallization, filter, and dry the filter cake under reduced pressure to obtain 4.88 g of 3-(4-nitrobenzene)-1,2,4-oxadiazole with a yield of 92.49% and a purity of 99.7%.

实施例10Example 10

向反应瓶中加入17.00g 4-硝基苄胺肟,60.50g原甲酸三乙酯,3.06g甲酸,加热至70±5℃反应3h,反应完成后滴加叔丁醇析晶,抽滤,滤饼减压干燥得3-(4-硝基苯)-1,2,4-噁二唑16.68g,收率92.98%,纯度99.8%。Add 17.00 g of 4-nitrobenzylamine oxime, 60.50 g of triethyl orthoformate, and 3.06 g of formic acid into the reaction bottle, heat to 70±5°C and react for 3 h. After the reaction is completed, add tert-butanol dropwise to crystallize, filter, and dry the filter cake under reduced pressure to obtain 16.68 g of 3-(4-nitrobenzene)-1,2,4-oxadiazole with a yield of 92.98% and a purity of 99.8%.

实施例11Embodiment 11

向反应瓶中加入5.00g 4-硝基苄胺肟,18.00g原甲酸三乙酯,0.25g甲酸,加热至100±5℃反应3h,取反应液送检,4-硝基苄胺肟原料剩余17.67%,无法完全转化。Add 5.00 g of 4-nitrobenzylamine oxime, 18.00 g of triethyl orthoformate, and 0.25 g of formic acid into the reaction bottle, heat to 100±5°C for 3 h, and send the reaction solution for inspection. The remaining 4-nitrobenzylamine oxime raw material is 17.67%, which cannot be completely converted.

Claims (6)

1.一种阿莫奈韦中间体3-(4-硝基苯)-1,2,4-噁二唑的制备方法,包括以下步骤:1. A method for preparing an amonetir intermediate 3-(4-nitrobenzene)-1,2,4-oxadiazole, comprising the following steps: (1)向4-硝基苄胺肟的原甲酸三乙酯溶液中,加入质子酸,升温反应;(1) Add protonic acid to a solution of 4-nitrobenzylamine oxime in triethyl orthoformate and heat to react; (2)反应结束后,加入溶剂析晶,分离固体即得3-(4-硝基苯)-1,2,4-噁二唑;(2) After the reaction is completed, a solvent is added to crystallize, and the solid is separated to obtain 3-(4-nitrobenzene)-1,2,4-oxadiazole; 所述步骤(1)中,所述质子酸选自甲酸、乙酸、丙酸、丁酸、甲烷磺酸、对甲苯磺酸、柠檬酸和草酸中的一种或多种。In the step (1), the protonic acid is selected from one or more of formic acid, acetic acid, propionic acid, butyric acid, methanesulfonic acid, p-toluenesulfonic acid, citric acid and oxalic acid. 2.根据权利要求1所述的制备方法,所述步骤(1)中,质子酸与4-硝基苄胺肟的摩尔比为0.3~0.7。2. The preparation method according to claim 1, wherein in step (1), the molar ratio of protonic acid to 4-nitrobenzylamine oxime is 0.3-0.7. 3.根据权利要求2所述的制备方法,所述步骤(1)中,所述质子酸为甲酸。3. The preparation method according to claim 2, wherein in step (1), the protonic acid is formic acid. 4.根据权利要求1所述的制备方法,所述步骤(1)中,升温反应时的温度为45~105oC。4. The preparation method according to claim 1, wherein in step (1), the temperature during the temperature-raising reaction is 45-105 ° C. 5.根据权利要求1所述的制备方法,所述步骤(2)中,所述溶剂选自甲醇、乙醇、正丙醇、异丙醇、正丁醇、异丁醇和叔丁醇中的一种或多种。5. The preparation method according to claim 1, wherein in step (2), the solvent is selected from one or more of methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol and tert-butanol. 6.根据权利要求5所述的制备方法,所述步骤(2)中,所述溶剂为乙醇或叔丁醇。6. The preparation method according to claim 5, wherein in step (2), the solvent is ethanol or tert-butanol.
CN202410226549.6A 2024-02-29 2024-02-29 Preparation method of amoenavir intermediate Pending CN118184599A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410226549.6A CN118184599A (en) 2024-02-29 2024-02-29 Preparation method of amoenavir intermediate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202410226549.6A CN118184599A (en) 2024-02-29 2024-02-29 Preparation method of amoenavir intermediate

Publications (1)

Publication Number Publication Date
CN118184599A true CN118184599A (en) 2024-06-14

Family

ID=91412836

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202410226549.6A Pending CN118184599A (en) 2024-02-29 2024-02-29 Preparation method of amoenavir intermediate

Country Status (1)

Country Link
CN (1) CN118184599A (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005336101A (en) * 2004-05-27 2005-12-08 Taoka Chem Co Ltd Method for producing phenyloxadiazole compound
CN103097340A (en) * 2010-07-16 2013-05-08 安吉奥斯医药品有限公司 Therapeutically active compositions and methods of use thereof
CN109311887A (en) * 2016-04-06 2019-02-05 溶酶体治疗股份有限公司 Pyrazolo[1,5-a]pyrimidinylcarboxamide compounds and their use in the treatment of medical conditions
US20200299282A1 (en) * 2019-03-20 2020-09-24 Antidote Ip Holdings, Llc Compounds and methods for treating cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005336101A (en) * 2004-05-27 2005-12-08 Taoka Chem Co Ltd Method for producing phenyloxadiazole compound
CN103097340A (en) * 2010-07-16 2013-05-08 安吉奥斯医药品有限公司 Therapeutically active compositions and methods of use thereof
CN109311887A (en) * 2016-04-06 2019-02-05 溶酶体治疗股份有限公司 Pyrazolo[1,5-a]pyrimidinylcarboxamide compounds and their use in the treatment of medical conditions
US20200299282A1 (en) * 2019-03-20 2020-09-24 Antidote Ip Holdings, Llc Compounds and methods for treating cancer

Similar Documents

Publication Publication Date Title
CN106866553B (en) Synthesis method of Favipiravir
CN102066297B (en) Method of purifying crude glycerol
US20090012321A1 (en) Process for preparing 17alpha-acetoxy-6-methylenepregn-4-ene-3,20-dione, medroxyprogesterone acetate and megestrol acetate
CN101959840A (en) Process for preparing alkyl 2-alkoxymethylene-4,4-difluoro-3-oxobutyrates
WO2012110947A1 (en) An improved process for preparation of levonorgestrel
CN118184599A (en) Preparation method of amoenavir intermediate
JP4892915B2 (en) Epalrestat manufacturing method
CN115260045A (en) Preparation process of high-purity esmolol hydrochloride
EP2097398B1 (en) Process of producing amorolfine free base
WO2022110612A1 (en) Preparation method for s-configuration phenylethylamine hydrochloride compound
EP1917254B1 (en) Process of producing amorolfine
CN110938075B (en) Ganciclovir preparation method
US20120253051A1 (en) Process for the preparation of ropinirole and salts thereof
CN115872873B (en) Recrystallization purification method of bis (2-bromoethyl) amine hydrobromide
CN116063192B (en) Synthesis method of dopamine hydrochloride
CN114195844A (en) Preparation method of dehydroepiandrosterone
CN1989108B (en) The preparation method of 2-hydroxyquinoline compound
CN114685509B (en) Preparation method of adefovir intermediate or hydrochloride thereof
US20080319226A1 (en) Process For the Preparation of Highly Pure (E) N,N-Diethyl-2-Cyano-3-(3,4-Dihydroxy-5-Nitro Phenyl) Acrylamide (Entacapone)
CN111303039A (en) Preparation method of imidazole antiviral compound
CN110615747A (en) Preparation method of indane intermediate
WO2016135616A1 (en) An improved process for the preparation of bisoprolol and its intermediate
CN104926890B (en) A kind of synthetic method of the O dibenzoyl ribose of 1,2 O diacetyls 3,5
CN108440374A (en) A kind of preparation method of acemetacin
CN102264717B (en) A process for manufacturing zeranol

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination